Current medical intervention in cancer therapeutic methods has shown risks and side effects with normal tissues. This includes incomplete cancer eradication. In reference to numerous studies and literature reviews, a stimuli-responsive drug delivery system is selected as an innovative, safe and more assured treatment due to its site-specific release ability. This allows specific intervention upon the given stimulus which response to the presenting disease symptoms. Hence, we designed a ROS(Reactive Oxygen Species)-responsive BA-ADA(4-Hydroxyphenylboronic acid pinacol ester and 1-Adamantanecarboxylic acid bonded molecule) nanoparticle delivery system. In our study, ROS-responsive nanoparticle was designed and prepared based on a synthetic molecule from BA and ADA. A therapeutic payload, Doxorubicin, can be loaded into the nanoparticles and it can be selectively released within cancerous tissues whereby ROS level is over-expressed. This will enhance both therapeutic efficiency and reduce side effects. The stability and ROS-responsiveness of the particle were proven in a series of evidence-based experiments. The results showed a significant difference in cell viability during the experiments with healthy and cancerous cell samples. Further research will be required to extend the experiment in vivo.